MA43667B1 - Nouveaux dérivés de pyrrolidine - Google Patents
Nouveaux dérivés de pyrrolidineInfo
- Publication number
- MA43667B1 MA43667B1 MA43667A MA43667A MA43667B1 MA 43667 B1 MA43667 B1 MA 43667B1 MA 43667 A MA43667 A MA 43667A MA 43667 A MA43667 A MA 43667A MA 43667 B1 MA43667 B1 MA 43667B1
- Authority
- MA
- Morocco
- Prior art keywords
- pyrrolidine derivatives
- new pyrrolidine
- new
- compound
- formula
- Prior art date
Links
- 150000003235 pyrrolidines Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 102000005600 Cathepsins Human genes 0.000 abstract 1
- 108010084457 Cathepsins Proteins 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
L'invention concerne un composé de formule (i) dans laquelle r1 et r2 sont définis comme dans la description et dans les revendications. Le composé de formule (i) peut être utilisé comme médicament contre le diabète, l'athérosclérose et d'autres affections liées à la cathepsine.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16157679 | 2016-02-26 | ||
| PCT/EP2017/053967 WO2017144483A1 (fr) | 2016-02-26 | 2017-02-22 | Nouveaux dérivés de pyrrolidine |
| EP17705662.9A EP3419970B1 (fr) | 2016-02-26 | 2017-02-22 | Nouveaux dérivés de pyrrolidine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA43667B1 true MA43667B1 (fr) | 2020-03-31 |
Family
ID=55443159
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA43667A MA43667B1 (fr) | 2016-02-26 | 2017-02-22 | Nouveaux dérivés de pyrrolidine |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US10689339B2 (fr) |
| EP (1) | EP3419970B1 (fr) |
| JP (1) | JP6952044B2 (fr) |
| KR (1) | KR102797060B1 (fr) |
| CN (1) | CN108699044B (fr) |
| AR (1) | AR107717A1 (fr) |
| AU (1) | AU2017224343B2 (fr) |
| CA (1) | CA3011652C (fr) |
| CL (1) | CL2018002347A1 (fr) |
| CO (1) | CO2018007756A2 (fr) |
| CR (1) | CR20180404A (fr) |
| DK (1) | DK3419970T3 (fr) |
| ES (1) | ES2775781T3 (fr) |
| HR (1) | HRP20200307T1 (fr) |
| HU (1) | HUE047842T2 (fr) |
| IL (1) | IL260130B (fr) |
| LT (1) | LT3419970T (fr) |
| MA (1) | MA43667B1 (fr) |
| MX (1) | MX381332B (fr) |
| MY (1) | MY196560A (fr) |
| PH (1) | PH12018501585B1 (fr) |
| PL (1) | PL3419970T3 (fr) |
| PT (1) | PT3419970T (fr) |
| RS (1) | RS59938B1 (fr) |
| RU (1) | RU2736498C1 (fr) |
| SG (1) | SG11201807074VA (fr) |
| SI (1) | SI3419970T1 (fr) |
| TW (1) | TWI740903B (fr) |
| UA (1) | UA122084C2 (fr) |
| WO (1) | WO2017144483A1 (fr) |
| ZA (1) | ZA201804120B (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3575284T3 (pl) | 2017-01-24 | 2021-12-27 | Astellas Pharma Inc. | Związek prolinamidu podstawiony fenylodifluorometylem |
| TWI846731B (zh) | 2018-09-18 | 2024-07-01 | 瑞士商赫孚孟拉羅股份公司 | 組織蛋白酶(cathepsin)S抑制劑之對抗抗藥抗體形成之用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ595073A (en) * | 2009-04-20 | 2012-11-30 | Hoffmann La Roche | Proline derivatives as cathepsin inhibitors |
| CN103930400B (zh) * | 2011-11-11 | 2016-04-20 | 霍夫曼-拉罗奇有限公司 | 制备1-酰基-4-苯基磺酰基脯氨酰胺衍生物的方法及中间体 |
| RU2014123784A (ru) * | 2011-11-25 | 2015-12-27 | Ф. Хоффманн-Ля Рош Аг | Новые производные пирролидина в качестве ингибиторов катепсина |
| CN104114068B (zh) * | 2011-12-09 | 2017-07-11 | W.C.布拉德利公司 | 具有可调整的加热特征的烹饪炉排 |
| EP2814822B1 (fr) * | 2012-02-17 | 2016-04-20 | F.Hoffmann-La Roche Ag | Nouveaux dérivés de pyrrolidine |
| PE20150995A1 (es) * | 2012-08-21 | 2015-06-29 | Hoffmann La Roche | Nuevos derivados de piridina |
-
2017
- 2017-02-22 CN CN201780013397.XA patent/CN108699044B/zh active Active
- 2017-02-22 UA UAA201809397A patent/UA122084C2/uk unknown
- 2017-02-22 CA CA3011652A patent/CA3011652C/fr active Active
- 2017-02-22 WO PCT/EP2017/053967 patent/WO2017144483A1/fr not_active Ceased
- 2017-02-22 SG SG11201807074VA patent/SG11201807074VA/en unknown
- 2017-02-22 PL PL17705662T patent/PL3419970T3/pl unknown
- 2017-02-22 CR CR20180404A patent/CR20180404A/es unknown
- 2017-02-22 KR KR1020187024347A patent/KR102797060B1/ko active Active
- 2017-02-22 AU AU2017224343A patent/AU2017224343B2/en active Active
- 2017-02-22 MY MYPI2018001465A patent/MY196560A/en unknown
- 2017-02-22 RU RU2018133640A patent/RU2736498C1/ru active
- 2017-02-22 SI SI201730195T patent/SI3419970T1/sl unknown
- 2017-02-22 MA MA43667A patent/MA43667B1/fr unknown
- 2017-02-22 EP EP17705662.9A patent/EP3419970B1/fr active Active
- 2017-02-22 HU HUE17705662A patent/HUE047842T2/hu unknown
- 2017-02-22 DK DK17705662.9T patent/DK3419970T3/da active
- 2017-02-22 JP JP2018541661A patent/JP6952044B2/ja active Active
- 2017-02-22 LT LTEP17705662.9T patent/LT3419970T/lt unknown
- 2017-02-22 ES ES17705662T patent/ES2775781T3/es active Active
- 2017-02-22 HR HRP20200307TT patent/HRP20200307T1/hr unknown
- 2017-02-22 PT PT177056629T patent/PT3419970T/pt unknown
- 2017-02-22 MX MX2018009638A patent/MX381332B/es unknown
- 2017-02-22 RS RS20200183A patent/RS59938B1/sr unknown
- 2017-02-24 TW TW106106388A patent/TWI740903B/zh active
- 2017-02-24 AR ARP170100467A patent/AR107717A1/es unknown
-
2018
- 2018-06-19 IL IL260130A patent/IL260130B/en active IP Right Grant
- 2018-06-20 ZA ZA2018/04120A patent/ZA201804120B/en unknown
- 2018-07-25 PH PH12018501585A patent/PH12018501585B1/en unknown
- 2018-07-26 CO CONC2018/0007756A patent/CO2018007756A2/es unknown
- 2018-08-16 CL CL2018002347A patent/CL2018002347A1/es unknown
- 2018-08-24 US US16/111,721 patent/US10689339B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA38239A1 (fr) | Nouveaux dérivés de pyridine | |
| MA38404A1 (fr) | Nouveaux dérivés de pyridine | |
| MA33224B1 (fr) | Derives de proline comme inhibiteurs de la cathepsine | |
| MA58087B1 (fr) | Nouveaux dérivés de méthylquinazolinone | |
| MA38403A1 (fr) | Nouveaux dérivés de pyrazole modulateurs specifiques de cb2 | |
| MA38826B1 (fr) | Nouveaux dérivés de triazolo[4,5-d]pyrimidine | |
| MA35663B1 (fr) | Dérivés de [1, 2, 3]triazolo [4, 5 -d] pyrimidine comme agonistes des récepteurs aux cannabinoïdes 2 | |
| MA45782B1 (fr) | Modulateurs du récepteur de cxcr7 pipéridine | |
| AR077014A1 (es) | Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer | |
| MX2016000307A (es) | Farmaco para el tratamiento de la esteatosis hepatica no alcoholica. | |
| MA38238B1 (fr) | Pyridine-2-amides utiles comme agonistes de cb2 | |
| ZA201706381B (en) | Molecules having pesticidal utility, and intermediates, compositions, and processes, related thereto | |
| EA201070786A1 (ru) | Бензофуропиримидиноны | |
| EA201070422A1 (ru) | Производные оксадиазола | |
| MA31759B1 (fr) | Compose amide | |
| MA31690B1 (fr) | Nouveaux fongicides | |
| JOP20210039B1 (ar) | مركبات بيريدين 6،2 - ديامينو | |
| MA33275B1 (fr) | Inhibiteurs de la replication du virus de l'immunodeficience humaine | |
| NO20084368L (no) | Stabile emulsjonsformuleringer | |
| EA200870216A1 (ru) | Амидо соединения и их применение в качестве лекарственных средств | |
| MA43400B1 (fr) | Dérivés de phényle en tant qu'agonistes du récepteur cannabinoïde 2 | |
| BRPI0812222A2 (pt) | Compostos ciclobutenodiona substituídos anti-inflamatórios. | |
| ATE554084T1 (de) | N-hydroxyacrylamidverbindungen | |
| EA201171339A1 (ru) | Способ снижения внутриглазного давления у людей | |
| MX2017006136A (es) | Moleculas que tienen utilidad plaguicida e intermediarios, composiciones y procedimientos relacionados con las mismas. |